Citations

Clear

3 citation(s) found for "Saokhieo, Preenapun".

Contemporary global epidemiology of cirrhosis
Saokhieo, Preenapun , Auttapracha, Thanida , Danpanichkul, Pojsakorn , Pang, Yanfang , Yang, Liu , Singal, Amit G. , Kim, Donghee , Wijarnpreecha, Karn , Auttapracha, Thanida , Singal, Amit , Wijarnpreecha, Karn , Kim, Donghee , Danpanichkul, Pojsakorn , Pang, Yanfang , Yang, Liu

Mayo Clinic

Hepatology Communications | July 16, 2026 | Volume: 10 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000989 | PMID 42486788 Get It

Cirrhosis remains a major global cause of morbidity and mortality, with rapidly evolving etiologic drivers. This review summarizes the contemporary global epidemiology of cirrhosis, highlighting regional patterns and major transitions in underlying causes to inform prevention and policy. In 2021, cirrhosis and chronic liver disease accounted for ~1.4 million deaths worldwide. Although age-standardized mortality rates have declined in many regions, the absolute burden continues to rise due to population growth and aging. Reductions in hepatitis B and C–related cirrhosis, driven by vaccination, screening, and antiviral therapy, have been offset by a growing contribution from steatotic liver disease. High–sociodemographic index (SDI) regions exhibit lower mortality but increasing prevalence, reflecting improved survival and expanding metabolic risk, whereas low- and lower-middle–SDI regions continue to experience high mortality. Addressing the global burden of cirrhosis will require sustained public health investment focused on viral hepatitis elimination, alcohol-associated harm reduction, metabolic risk management, and equitable access to early detection and care.
Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries
Danpanichkul, Pojsakorn , Pang, Yanfang , Tothanarungroj, Primrose , Dejvajara, Disatorn , Kim, Donghee, Saokhieo, Preenapun , Suparan, Kanokphong, Bernal, Diego Olavarria , Lui, Rashid N., Wijarnpreecha, Karn, Wallace, Michael, Roberts, Lewis R. , Singal, Amit G., Yang, Ju Dong, Kim, Donghee , Suparan, Kanokphong , Abou-Alfa, Ghassan K , Singal, Amit , Yang, Ju Dong , Roberts, Lewis R , Kim, Donghee , Danpanichkul, Pojsakorn , Muthiah, Mark D , Duangsonk, Kwanjit , Lui, Rashid , Wijarnpreecha, Karn , Abou‐Alfa, Ghassan K. , Singal, Amit G.

Mayo Clinic

Cancer | December 30, 2025 | Volume: 132 | Issue: 1 | Pages: No page available

10.1002/cncr.70245 | PMID 41468237 Get It

Abstract Background Gastrointestinal (GI) cancer remains a major global health challenge. This study provides updated 2022 estimates of GI cancer incidence and mortality worldwide, along with projections of incident cases and deaths through 2050 to inform cancer control strategies. Methods In this population‐based study, data from the GLOBOCAN 2022 database were used to examine incidence and deaths associated with GI cancer. By using global demographic projections, this study estimated the projected number of incident cases and deaths until the year 2050. Results By 2050, the global burden of GI cancer is projected to reach 9.06 million incident cases (+85%) and 6.42 million deaths (+93%) from 2022. Increases in incidence are projected for both females (+87%) and males (+83%), as are increases in mortality for both females (+97%) and males (+91%). Whereas the Western Pacific region will have the highest absolute burden, with 3.88 million new cases and 2.79 million deaths, the greatest relative increase is expected in Africa, with incidence and deaths rising by 157% and 160%, respectively. As measured by the Human Development Index (HDI), the steepest increases are projected in low (+151% incidence; +152% deaths) and medium (+112% incidence; +114% deaths) HDI countries. Overall, all GI cancer types are projected to increase, led by pancreatic cancer in incidence (+95%) and colorectal cancer in deaths (+103%). Conclusions GI cancer incidence and deaths are expected to nearly double by 2050, with increases across sexes, cancer types, and regions, especially in lower HDI countries.
Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021
Danpanichkul, Pojsakorn , Chen, Vincent , Saokhieo, Preenapun , Dejvajara, Disatorn , Sukphutanan, Banthoon , Lopimpisuth, Chawin , Pang, Yanfang , Fallon, Michael B. , Kim, Donghee , Yang, Ju Dong , Aqel, Bashar , Chen, V L , Saokhieo, Preenapun , Huang, Daniel Q , Kim, Donghee , Singal, Amit , Yang, Ju Dong , Aqel, Bashar A. , Terrault, Norah , Wijarnpreecha, Karn , Danpanichkul, Pojsakorn , Duangsonk, Kwanjit , Aboona, Majd B. , Ibrahim, Andrew , Huang, Daniel Q. , Singal, Amit G. , Terrault, Norah A. , Wijarnpreecha, Karn

Mayo Clinic

Hepatology | February 12, 2025 | Volume: 82 | Issue: 5 | Pages: 1274-1286

10.1097/hep.0000000000001260 | PMID 39937958 Get It

Backgrounds and Aims: HBV-related liver disease ranks as the seventh leading cause of mortality. Despite advances in prevention and treatment, global disparities in the burden of primary liver cancer (PLC) persist. We evaluate global trends in the prevalence, incidence, and death of HBV-related liver disease. Approach and Results: Data from the Global Burden of Disease Study 2021 evaluated acute HBV infection, HBV-related cirrhosis, and HBV-related liver cancer prevalence, incidence, and death. In 2021, there were 7.30 million cases of acute HBV, 283.64 million cases of HBV-related cirrhosis, and 288,110 cases of HBV-related PLC. HBV-related PLC accounted for 39% of the global incidence of PLC; Western Pacific had the highest rates for HBV-related PLC, with an incidence of 5.24 and a death rate of 4.38 per 100,000 population. Between 2000 and 2021, age-standardized incidence, prevalence, and death rates from HBV-related liver disease decreased; however, the incidence of HBV-related PLC rose in 65 countries from 2000 to 2021. In parallel, age-standardized prevalent rates from HBV-related PLC increased in Europe (annual percent change: 0.77%, 95% CI: 0.72%–0.81%) and the Americas (annual percent change: 1.05%, 95% CI: 1.00%–1.10%). Conclusions: From 2000 to 2021, decreases in HBV-related liver disease incidence and prevalence were observed; however, more than one-third of countries showed an increase in the incidence of HBV-related PLC. These findings highlight the need for strengthened HBV treatment efforts to reduce the risk of liver cancer.